Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer

The combination of Opdivo and Yervoy showed a survival advantage in renal cancer in a Phase III trial, adding to the understanding that overall survival may be a better endpoint than progression-free survival for measuring immuno-oncology drugs.

Digital illustration of Cancer cell in colour background

Immuno-oncology combinations have faced disappointing clinical trial data of late, but positive news from Bristol-Myers Squibb Co.'s Phase III trial testing its PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) in advanced renal cell cancer could swing the pendulum back in their favor.

Bristol announced top-line data from an interim analysis of the Phase III CheckMate 214 study testing the combination in advanced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer